Embraer Q3 Beat and Raised Guidance Shift Thesis from Wait to Buy

What happened

Embraer's Q3 2026 operating results exceeded expectations, driven by a strong performance in Services & Support, and management raised full-year revenue guidance. The firm-order backlog grew to $35.7 billion, up from $31.6 billion at the end of 2025, indicating sustained demand and no additional customer order resets beyond the earlier Azul reduction. The stock now trades at 12.9x EBITDA, a discount to the peer average of 15.3x, suggesting the market has not fully priced in the improved outlook. These results address key concerns from the prior analysis: production leveling is showing in delivery cadence, and customer distress appears contained. The risk/reward has shifted favorably, supporting a more constructive stance on Embraer shares.

Implication

The strong Q3 results and raised guidance indicate that management's production leveling efforts are delivering tangible results, reducing the seasonality that previously weighed on cash flow predictability. The growth in backlog to $35.7 billion, with Services & Support leading, suggests that the installed base is monetizing effectively and that customer demand remains robust despite prior concerns about airline credit stress. The stock's valuation at 12.9x EBITDA, a 16% discount to peers, implies the market has not yet fully rewarded Embraer for its improved execution and backlog quality, leaving room for multiple expansion. While risks remain, such as potential future customer renegotiations or supply-chain disruptions, the evidence from the first three quarters of 2026 supports a shift from a wait-and-see approach to a more constructive stance. A reasonable entry point is now, with an eye toward the $75-80 range based on peer multiple convergence, though investors should monitor quarterly delivery cadence and backlog changes for any early warning signs.

Thesis delta

The prior WAIT thesis was predicated on the need for evidence that production leveling would reduce delivery bunching and that no further customer distress would emerge beyond Azul. The Q3 2026 beat, raised guidance, and $35.7 billion backlog provide that evidence, indicating execution is improving and demand is resilient. Consequently, the thesis shifts to a BUY with an implied value near $75-80, supported by peer-multiple convergence and a strong Services & Support mix.